Huadong Medicine Partners with Excientia, a UK-based AI Drug Discovery Company

Huadong Medicine formed a partnership with Exscientia, an AI drug discovery company in the UK , to discover novel small-molecule candidates for oncology. The initial project is focused on transcription control of DNA damage response genes. The approach will treat patients with defective DNA damage repair mechanisms, a condition that leads to high mutation frequency, in patients with ovarian and breast cancer. The partnership will advance Huadong's strategic goal of developing innovative medicines. More details.... Stock Symbol: (SHZ: 0963) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.